Literature DB >> 21461581

Immunoactivative role of indoleamine 2,3‑dioxygenase in gastric cancer cells in vitro.

Rupeng Zhang1, Hui Li, Jinpu Yu, Jingzhu Zhao, Xuejun Wang, Gang Wang, Zhoujia Yao, Feng Wei, Qiang Xue, Xiubao Ren.   

Abstract

To study the role of indoleamine 2,3-dioxygenase (IDO) in immune response and immune escape in gastric cancer, the human IDO gene was cloned by reverse transcription-polymerase chain reaction (RT-PCR) and inserted into the pIRES2-EGFP vector to construct the IDO expression vector (pIRES2-EGFP-IDO). BGC-823 cells were transfected with the vector by electroporation and selected stable expression with G418. IDO expression was determined by RT-PCR and Western blot analysis. The enzymatic activity of IDO was estimated by determining tryptophan and kynurenine concentrations in the cell culture medium by an amino acid analyzer. To assess the effect of IDO on T cell-mediated cytotoxicity and proliferation, T cells from patients with gastric cancer were co-cultured with the IDO-transfected BGC-823 cells in the presence or absence of 1-MT, a competitive inhibitor of IDO. Cells transfected with the vector expressed high levels of IDO mRNA and protein, and a significantly higher level of kynurenic acid was detected in the culture medium of the transfected cells compared to the non-transfected cells (P<0.001). T cells co-cultured with the IDO-transfected cells exhibited significantly lower cytotoxicity compared to the control group (P<0.05). Additionally, IDO-transfected cells treated with 1-MT exhibited higher toxicity compared to the untreated IDO-transfected cells (P<0.01). We conclude that IDO plays a key role in gastric cancer immune suppression, possibly by inhibiting T cell-mediated cytotoxicity and proliferation in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21461581     DOI: 10.3892/mmr.2010.398

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

Review 2.  Current therapeutic landscape for advanced gastroesophageal cancers.

Authors:  Anthony Lopez; Kazuto Harada; Dilsa Mizrak Kaya; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2018-02

3.  The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer.

Authors:  Rupeng Zhang; Hui Liu; Fangxuan Li; Hui Li; Jinpu Yu; Xiubao Ren
Journal:  Dig Dis Sci       Date:  2013-08-25       Impact factor: 3.199

4.  Differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jingshen Tian; Weinan Xue; Huihui Yin; Nannan Zhang; Junde Zhou; Zhiping Long; Chengwei Wu; Zhengzi Liang; Kun Xie; Shuo Li; Liangliang Li; Zhen Wu; Volontovich Daria; Yashuang Zhao; Fan Wang; Maoqing Wang
Journal:  Onco Targets Ther       Date:  2020-06-25       Impact factor: 4.147

5.  CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.

Authors:  Fangxuan Li; Yao Sun; Jinchao Huang; Wengui Xu; Juntian Liu; Zhiyong Yuan
Journal:  Cancer Med       Date:  2019-10-20       Impact factor: 4.452

6.  Kynurenine and Anthranilic Acid in the Peritoneum Correlate With the Stage of Gastric Cancer Disease.

Authors:  Katarzyna Gęca; Karol Rawicz-Pruszyński; Radosław Mlak; Ilona Sadok; Wojciech P Polkowski; Magdalena Staniszewska
Journal:  Int J Tryptophan Res       Date:  2022-02-02

7.  Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Jiaqi Huang; Alison M Mondul; Stephanie J Weinstein; Stella Koutros; Andriy Derkach; Edward Karoly; Joshua N Sampson; Steven C Moore; Sonja I Berndt; Demetrius Albanes
Journal:  Br J Cancer       Date:  2016-09-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.